Den estimerede frekvens af patienter fri for progressions til fremskreden fase eller blastkrise efter 60 måneder var signifikant højere i Glivec- armen end i IFN- armen (92, 9% versus 86, 2%, p < 0, 001).
The estimated rate of patients free of progression to accelerated phase or blast crisis at 60 months was significantly higher in the Glivec arm compared to the IFN arm (92.9% versus 86.2%, p < 0.001).